GBrain MRI

The GBrain MRI is a post-processing software designed to automatically segment, quantify, and report signal hyperintensities on FLAIR MR brain images, providing quantitative metrics to aid diagnostic radiology without replacing physician evaluation. Its core science involves advanced image processing algorithms for precise automated analysis, confirmed through performance testing to accurately segment hyperintensities for clinical use.

The GBrain MRI device, developed by Galileo CDS, Inc., received a substantial equivalence determination on February 12, 2025, allowing its marketing for specific indications. This Class II medical image management and processing system is subject to general regulatory controls, including annual registration, device listing, good manufacturing practices, and proper labeling, ensuring its compliance within the medical device market. The device functions as post-processing software designed for analyzing and quantitatively reporting signal hyperintensities observed on FLAIR MR images of the brain, within the field of diagnostic radiology. It achieves this through automatic segmentation, quantification, and generation of derived image metrics, which were confirmed for accuracy during performance testing for clinical practice. Importantly, the GBrain MRI is explicitly not intended for disease detection, specific diagnosis of hyperintensities, or to replace a physician's comprehensive evaluation of patient MRI scans, maintaining the physician's ultimate diagnostic responsibility.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific quantitative metrics are reported by the GBrain MRI software, and how are these metrics standardized across different MRI scanners or protocols?; How does the device's automatic segmentation accuracy for signal hyperintensities compare to manual segmentation by expert neuroradiologists, particularly in cases with ambiguous lesion boundaries or artifacts?; Given that the software is not intended for diagnosis, what clinical use cases or research scenarios benefit most significantly from its quantitative reporting capabilities?; What ongoing validation studies or post-market surveillance are planned or required to monitor the device's performance and identify potential limitations in diverse patient populations or disease states?; How does the GBrain MRI integrate with existing Picture Archiving and Communication Systems (PACS) or other hospital IT infrastructure, and what are the system requirements for its optimal operation?